Navigation Links
Millennium Over-Delivers on 2007 Goals and Financial Guidance
Date:2/7/2008

- Worldwide VELCADE(R) (bortezomib) for Injection sales surpassed $765

million in 2007 -

- VELCADE granted priority review by FDA in newly diagnosed multiple

myeloma, with launch on track for first half of 2008 -

CAMBRIDGE, Mass., Feb. 7 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported 2007 non-GAAP net income of $86.9 million and GAAP net income of $14.9 million.(1) These results exceeded the Company's 2007 financial guidance, driven by strong worldwide sales of VELCADE, the global market leader for the treatment of patients with relapsed multiple myeloma.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"Millennium over-delivered on high expectations in 2007, including the achievement of record financial results," said Deborah Dunsire, M.D., President and Chief Executive Officer. "Millennium is uniquely situated for growth with a blockbuster oncology product, a pipeline of innovative product candidates and strong financials."

"We remain committed to positioning the Company to deliver sustainable earnings growth," stated Marsha Fanucci, Chief Financial Officer. "In 2008, the Company is focused on elevating its success by maximizing the launch of VELCADE in newly diagnosed multiple myeloma, initiating a pivotal trial program with MLN0002 in inflammatory bowel disease and achieving our financial guidance."

2007 Financial Results

-- The Company achieved full-year non-GAAP net income of $86.9 million or

non-GAAP earnings per share of $0.27. The 125 percent increase over

non-GAAP net income in
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
2. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
3. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Life Sciences Leader Joins Millennium Board of Directors
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
10. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
11. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... announced that it will release its unaudited financial results for ... on Thursday, August 14, 2014 EDT. The Company will host ... August 15, 2014, at 8:00 a.m. EDT (Friday, August 15, ... Company,s financial results and provide an update on recent corporate ...
(Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
(Date:7/24/2014)... Yushan Yan, Distinguished Professor of Engineering at the ... nanomaterials to solve problems in energy engineering, environmental ... focused on zeolites, porous rock with a well-defined, ... size is so precisely decided that zeolites can ... fraction of an angstrom (one-tenth of a nanometer), ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2
... SANTA MONICA, Calif., May 19 Cord Blood America, Inc. ... preservation company ( http://www.cordblood-america.com ) focused ... families nationwide and internationally, announced today that it will hold ... Eastern time to discuss 2009 first quarter results for the ...
... Million in New Projects Approved in Atlanta ATLANTA, ... bioscience and biotechnology convention, the Kansas Bioscience Authority ... investments as part of a $581 million initiative ... state.The funding decisions made at the Bio International ...
... -- Prototype of the Innovative Combined Technology on ... 19 Hospira, Inc. (NYSE: HSP ... delivery company, today announced the coming integration of ... EndoTool(R) glucose management software. A prototype of this ...
Cached Biology Technology:Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments 2As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 2As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 3As Other States Pull Back, Kansas Accelerates Innovation Investments at Bio International Convention 4Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies 2Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies 3
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... on average over a 35 year period in which ... impact of humans on declining animal numbers. This decline ... insects, spiders, crustaceans, slugs and worms bring to our ... decomposition for nutrient cycling, water filtration and human health. ... led by UCL, Stanford and UCSB, focused on the ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... A gynecologist and a molecular biologist at UT Southwestern Medical Center ... prolapse a condition in which the uterus, bladder or vagina ... a loss of elasticity and a breakdown of proteins in the ... than 50 years of age. Besides creating pelvic pressure, prolapse can ...
... Scientists have long known that people who have a ... of starting to abuse alcohol. The reason for this has ... of Gothenburg, Sweden, provides part of the answer. The study ... an alcoholic react more positively to alcohol than other people. ...
... be published online this week in the Proceedings of ... of a novel hepatitis C-like virus in dogs. The ... into how hepatitis C in humans may have evolved and ... study how it causes disease. The research was ...
Cached Biology News:UT Southwestern researchers find protein breakdown contributes to pelvic organ prolapse 2Heredity behind subjective effects of alcohol 2Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 2Discovery of canine hepatitis C virus opens up new doors for research on deadly human pathogen 3
... ZMD.473. Immunogen: Synthetic peptide derived ... mouse junctophilin-2. Specificity: Specific for ... (positive controls: mouse skeletal muscle homogenates ... Applications: Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store ...
Laminin gamma-2 (G-16)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Syd-2 (cL-19)...
Biology Products: